John Mikhail, MD
Pulmonary Disease · Ocean, NJNPI 1205173762
Payments from drug & device makers
Across 409 payments — averaging $25.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Sanofi$2K
- Boehringer Ingelheim$1K
- Regeneron Healthcare Solutions, Inc.$569
- Amgen$380
- plus $2K from 25 others
What the payments were for
- Consulting fees$1,46414%
- Food & beverage$8,63382%
- Education$4374%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 75 | $2,516 |
| GSK | 120 | $1,955 |
| Sanofi | 26 | $1,895 |
| Boehringer Ingelheim | 53 | $1,362 |
| Regeneron Healthcare Solutions, Inc. | 23 | $569 |
| Amgen | 21 | $380 |
| Insmed, Inc. | 10 | $232 |
| United Therapeutics Corporation | 10 | $204 |
| Philips North America LLC | 10 | $159 |
| Sanofi-aventis U.S. LLC | 2 | $157 |
| Mylan Specialty L.p. | 9 | $151 |
| Mallinckrodt Hospital Products Inc. | 4 | $141 |
| Actelion Pharmaceuticals US, Inc. | 8 | $126 |
| Intuitive Surgical | 1 | $94 |
| Inspire Medical Systems, Inc. | 3 | $72 |
| Grifols USA, LLC | 4 | $51 |
| Advanced Respiratory, Inc | 3 | $51 |
| Boston Scientific | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Pfizer | 3 | $45 |
| Genentech USA, Inc. | 3 | $42 |
| Jazz Pharmaceuticals Inc. | 3 | $40 |
| Vifor Pharma, Inc. | 2 | $34 |
| Verona Pharma, Inc. | 2 | $34 |
| Viatris Specialty LLC | 2 | $33 |
| Electromed, Inc. | 2 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Apria Healthcare LLC | 1 | $17 |
| Circassia Inc. | 1 | $14 |
| Harmony Biosciences LLC | 1 | $13 |
| Covis Pharma GmbH | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$776
- FASENRA$674
- BREZTRI$600
- BEVESPI AEROSPHERE$282
- AIRSUPRA$282
- OFEV$231
- DUPIXENT$135
- NUCALA$125
- TRELEGY ELLIPTA$115
- AREXVY$111
How this compares
$10,534 in reported general payments places this provider in the 80th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 36 | $467,257 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 491 | $393,277 |
| Dupixent PenDupilumab | 48 | $194,344 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 14 | $145,065 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 132 | $89,217 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 103 | $54,484 |
| Breo ElliptaFluticasone/Vilanterol | 92 | $46,901 |
| Spiriva RespimatTiotropium Bromide | 34 | $29,978 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 33 | $24,257 |
| EliquisApixaban | 21 | $15,392 |
| Incruse ElliptaUmeclidinium Bromide | 35 | $12,142 |
| Advair HfaFluticasone Propion/Salmeterol | 24 | $10,531 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 229 | $8,894 |
| Arnuity ElliptaFluticasone Furoate | 24 | $8,103 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $5,708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,362 | $521,492103 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,955 | $514,905745 claims |
| Grifols USA, LLCProlastin C | $51 | $145,06514 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,516 | $99,810166 claims |
| PfizerEliquis | $45 | $15,39221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Ocean
- James CosentinoOcean$18K
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
- Manuel CunananMillville$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.